Boston Scientific sees Q3 adjusted EPS 46c-48c, consensus 48c

Sees Q3 revenue up 8.5%-10.5%, consensus $3.44B. The company said, “The company estimates net sales growth for the third quarter of 2023, versus the prior year period, to be in a range of approximately 8.5 to 10.5 percent on a reported basis, and approximately 7 to 9 percent on an organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.21 to $0.25 and adjusted EPS, excluding certain charges (credits), of $0.46 to $0.48.”